Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Intensive Care Medicine
Published in: Intensive Care Medicine 7/2010

01-07-2010 | Correspondence

Oseltamivir carboxylate accumulation in a patient treated by haemodiafiltration and extracorporeal membrane oxygenation

Authors: Florian Lemaitre, Charles-Edouard Luyt, François Roullet-Renoleau, Ania Nieszkowska, Noël Zahr, Christine Fernandez, Robert Farinotti, Alain Combes

Published in: Intensive Care Medicine | Issue 7/2010

Login to get access

Excerpt

Oseltamivir is a neuraminidase inhibitor licensed for treatment of influenza A and B. The recommended dosage is 75 mg BID for 5 days. However higher dosage of oseltamivir (150 mg BID) and increased duration of therapy may be applied in severe cases with evidence of clinical progression [1]. The French Drug Agency (AFSSAPS) also recommended this dosage for severe influenza A/H1N1. …
Literature
1.
Napolitano LM, Park PK, Sihler KC, Papadimos T, Chenoweth C, Cinti S, Zalewski C, Sharangpani R, Somsel P, Wells E, Fry AM, Fiore AE, Villanueva JM, Lindstrom S, Uyeki TM, Center for Disease Control (2009) Intensive-care patients with severe novel influenza A (H1N1) virus infection. MMWR Morb Mortal Wkly Rep 58:749–752
2.
Firstenberg MS, Blais D, Louis LB, Stevenson KB, Sun B, Mangino JE (2009) Extracorporeal membrane oxygenation for pandemic (H1N1) 2009. Emerg Infect Dis 15:2059–2060CrossRefPubMed
3.
Ruiz S, Papy E, Da Silva D, Nataf P, Massias L, Wolff M, Bouadma L (2009) Potential voriconazole and caspofungin sequestration during extracorporeal membrane oxygenation. Intensive Care Med 35:183–184CrossRefPubMed
4.
Robson R, Buttimore A, Lynn K, Brewster M, Ward P (2006) The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 21:2556–2562CrossRefPubMed
5.
Metadata
Title
Oseltamivir carboxylate accumulation in a patient treated by haemodiafiltration and extracorporeal membrane oxygenation
Authors
Florian Lemaitre
Charles-Edouard Luyt
François Roullet-Renoleau
Ania Nieszkowska
Noël Zahr
Christine Fernandez
Robert Farinotti
Alain Combes
Publication date
01-07-2010
Publisher
Springer-Verlag
Published in
Intensive Care Medicine / Issue 7/2010
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-010-1882-9

Other articles of this Issue 7/2010

Intensive Care Medicine 7/2010 Go to the issue

Pediatric Original

A 20-year experience on neonatal extracorporeal membrane oxygenation in a referral center

Experimental

Terlipressin versus adrenaline in an infant animal model of asphyxial cardiac arrest

Correspondence

Reply to Andrade and Pallin

Brief Report

Clinical relevance of 13 cytokine gene polymorphisms in Chinese major trauma patients

Correspondence

Esomeprazole-induced rhabdomyolysis in a patient with heart failure

Correspondence

Guillain–Barré syndrome related to pandemic influenza A (H1N1) infection